Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The colonic and intestinal epithelial ion and fluid transport machinery is a coordinated system of channels, transporters, and pumps that regulate the movement of water and electrolytes across the intestinal wall (Barrett & Keely, 2015, PMID: 25801028). This machinery includes key proteins such as the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), which mediates chloride secretion, and the Sodium-Hydrogen Exchanger 3 (NHE3), which facilitates sodium absorption (Engevik et al., 2020, PMID: 32164757). Proper functioning of this system is vital for maintaining luminal fluidity and systemic hydration. In diseases like Irritable Bowel Syndrome with Constipation (IBS-C), the machinery is targeted to increase fluid secretion, whereas in secretory diarrheas, such as those caused by Cholera toxin, the system is overstimulated (Field, 2003, PMID: 12499343). Drugs like linaclotide and tenapanor therapeutically modulate these pathways to restore normal bowel function (Layer & Stanghellini, 2014, PMID: 24861556). This system also involves the Epithelial Sodium Channel (ENaC) and various potassium channels that maintain the electrical gradient necessary for sustained transport (Kunzelmann & Mall, 2002, PMID: 11807181). Overall, this machinery represents a critical interface between the body and the external environment, balancing nutrient uptake with waste elimination.
Mechanisms include Guanylate Cyclase-C (GC-C) agonism leading to CFTR-mediated chloride and bicarbonate secretion (e.g., linaclotide), inhibition of the Sodium-Hydrogen Exchanger 3 (NHE3) to reduce sodium absorption (e.g., tenapanor), and activation of type-2 chloride channels (ClC-2) to enhance fluid movement (e.g., lubiprostone) (Schiller, 2017, PMID: 28607554). Additionally, inhibition of CFTR and calcium-activated chloride channels (CaCC) can be used to treat secretory diarrhea (e.g., crofelemer) (Tradtrantip et al., 2010, PMID: 20410299).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Colonic and intestinal epithelial ion and fluid transport machinery.